Arecor CEO Sarah Howell Presents Positive Phase I Trial Results of AT278 at EASD Conference

Proactive - Interviews for investors

Arecor CEO Sarah Howell and Principal Investigator Professor Thomas Pieber joined Steve Darling from Proactive to share promising updates from the company’s Phase I clinical trial of AT278, an ultra-concentrated, ultra-rapid acting insulin candidate designed for people with Type 2 diabetes and high body mass index (BMI). The trial results were presented at the prestigious 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, garnering significant attention. Howell explained that AT278 is a novel insulin formulation that accelerates insulin absorption following injection, even at high concentrations, which allows for lower injection volumes. In a double-blind, randomized, two-way crossover study, AT278 demonstrated a significantly faster pharmacokinetic (PK) and pharmacodynamic (PD) profile compared to NovoRapid® in Type 2 diabetes patients with high BMI. These results confirm previous findings in Type 1 diabetes patients, showing that AT278 can maintain its rapid action profile regardless of diabetes type or patient BMI. Pieber says this breakthrough is seen as a critical development in the pursuit of next-generation, miniaturized insulin pumps, which could offer patients greater convenience and improve their quality of life. Additionally, the trial reported a favorable safety profile, with no safety concerns detected, further supporting the potential of AT278 as a game-changing therapy for diabetes management. Arecor is now exploring various funding options, including potential co-development partnerships, to move forward with a clinical pump study. This study aims to further demonstrate AT278’s ability to enable truly miniaturized, longer-wear insulin pumps, which are highly sought after by both patients and healthcare providers, and hold the potential to significantly disrupt the diabetes treatment market. #proactiveinvestors #arecortherapeuticsplc #aim #arec #sarahhowell # #DiabetesCare #AT278 #InsulinTherapy #BiotechInnovation #DiabetesTreatment #PharmaResearch #Phase1Trial #MedicalBreakthroughs #FastActingInsulin #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews